Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: JAMA Oncol. 2015 Jul;1(4):486–494. doi: 10.1001/jamaoncol.2015.1432

Table.

Univariate and Multivariate Models for Overall Survival, Progression-Free Survival, and Platinum-Free Survival in Women With Ovarian Cancer in the Cancer Genome Atlas (TCGA) Discovery Cohorta

Characteristic Univariate Analysis
Multivariate Analysisb
HR (95% CI) P Valuec HR (95% CI) P Valuec
Overall Survival
ADAMTS status
 Wild type 1 [Reference] .01 1 [Reference] .004
 Mutation 0.36 (0.17–0.79) 0.32 (0.14–0.69)
BRCA1 or BRCA2 status
 Wild type 1 [Reference] .001 1 [Reference] .002
 Mutation 0.36 (0.20–0.64) 0.40 (0.22–0.72)
Tumor stage
 II 1 [Reference] .24 1 [Reference] .24
 III or IV 1.27 (0.40–4.00) 2.32 (0.56–9.50)
Residual tumor size, mm
 0d 1 [Reference] 1 [Reference]
 1–20 2.07 (1.17–3.66) .01 1.91 (1.08–3.39) .03
 >20 2.17 (1.08–4.37) .03 1.59 (0.79–3.24) .20
Age at diagnosis, y 1.01 (0.99–1.03) .20 1.02 (1.00–1.03) .09
Progression-Free Survival
ADAMTS status
 Wild type 1 [Reference] .003 1 [Reference] .001
 Mutation 0.46 (0.28–0.77) 0.42 (0.25–0.71)
BRCA1 or BRCA2 status
 Wild type 1 [Reference] .006 1 [Reference] .009
 Mutation 0.59 (0.40–0.86) 0.58 (0.39–0.88)
Tumor stage
 II 1 [Reference] .26 1 [Reference] .18
 III or IV 1.67 (0.69–4.08) 2.00 (0.73–5.47)
Residual tumor size, mm
 0d 1 [Reference] 1 [Reference]
 1–20 1.89 (1.26–2.83) .002 1.90 (1.26–2.86) .002
 >20 1.82 (1.11–2.98) .02 1.56 (0.94–2.60) .08
Age at diagnosis, y 1.00 (0.98–1.01) .56 1.00 (0.98–1.01) .47
Platinum-Free Survival
ADAMTS status
 Wild type 1 [Reference] .005 1 [Reference] .002
 Mutation 0.48 (0.29–0.80) 0.43 (0.26–0.73)
BRCA1 or BRCA2 status
 Wild type 1 [Reference] .01 1 [Reference] .01
 Mutation 0.60 (0.41–0.89) 0.59 (0.39–0.89)
Tumor stage
 II 1 [Reference] .18 1 [Reference] .21
 III or IV 1.83 (0.75–4.47) 1.91 (0.70–5.23)
Residual tumor size, mm
 0d 1 [Reference] 1 [Reference]
 1–20 1.86 (1.24–2.79) .003 1.88 (1.25–2.83) .03
 >20 1.84 (1.11–3.03) .02 1.60 (0.96–2.69) .07
Age at diagnosis, y 1.00 (0.98–1.01) .63 1.00 (0.98–1.01) .50

Abbreviation: HR, hazard ratio.

a

Included are data from the 210 TCGA patients with ovarian cancer who had an explicitly defined chemotherapy response status. Patient characteristics are detailed in eTable 1 in the Supplement. BRCA mutations include somatic and germline mutations of BRCA1 and BRCA2. Both ADAMTS and BRCA1 and BRCA2 mutations are depicted in Figure 1.

b

Based on a multivariate Cox proportional hazards model, including all variables in the table.

c

Wald test.

d

Patients with no macroscopic disease are categorized as 0 mm.